Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against Candida spp.

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 2, 2014, Pages 198-204

  Pfaller, Michael A ^a   Castanheira, Mariana ^a   Messer, Shawn A ^a   Rhomberg, Paul R ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Candida; CLSI; EUCAST; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL AND LABORATORY STANDARDS INSTITUTE METHOD; CONCENTRATION RESPONSE; CONTROLLED STUDY; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING; FUNGAL STRAIN; FUNGUS ISOLATION; INTERMETHOD COMPARISON; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SPECIES COMPARISON; STANDARD; WILD TYPE; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTIFUNGAL AGENTS; CANDIDA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84900492654     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.03.004     Document Type: Article

References (40)

1. Alastruey-Izquierdo A., Cuenca-Estrella M. EUCAST and CLSI: how to assess in vitro susceptibility and clinical resistance. Curr Fungal Infect Rep 2012, 6:229-234.
2. Arendrup M.C., Garcia-Effron G., Lass-Florl C., Lopez A.G., Rodriguez-Tudela J.L., Cuenca-Estrella M., et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 2010, 54:426-439.
3. Arendrup M.C., Rodriguez-Tudela J.L., Park S., Garcia-Effron G., Delmas G., Cuenca-Estrella M., et al. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother 2011, 55:1580-1587.
4. Arendrup M.C., Cuenca-Estrella M., Lass-Florl C. EUCAST Technical Note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012, 18:E246-E247.
5. Arendrup M.C., Dzajic E., Jensen R.H., Johansen H.K., Kjaeldgaard P., Knudsen J.D., et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013, 19:E343-E353.
6. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method. J Clin Microbiol 2001, 39:4181-4183.
7. Cleveland A.A., Farley M.M., Harrison L.H., Stein B., Hollick R., Lockhart S.R., et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55:1352-1361.
8. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement (M27-S3) 2008, CLSI, Wayne, PA.
9. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts 2008, CLSI, Wayne, PA. 3rd ed., M27-A3.
10. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement 2012, CLSI, Wayne, PA.
11. Espinel-Ingroff A., Pfaller M., Messer S.A., Knapp C.C., Killian S., Norris H.A., et al. Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J Clin Microbiol 1999, 37:591-595.
12. Espinel-Ingroff A., Pfaller M., Messer S.A., Knapp C.C., Holliday N., Killian S.B. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol 2004, 42:718-721.
13. Espinel-Ingroff A., Barchiesi F., Cuenca-Estrella M., Pfaller M.A., Rinaldi M., Rodriguez-Tudela J.L., et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005, 43:3884-3889.
14. Espinel-Ingroff A., Cuenca-Estrella M., Canton E. EUCAST and CLSI: working together towards a harmonized method for antifungal susceptibility testing. Curr Fungal Infect Rep 2013, 7:59-67.
15. Espinel-Ingroff A., Arendrup M.C., Pfaller M.A., Bonfietti L.X., Bustamante B., Canton E., et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?. Antimicrob Agents Chemother 2013, 57:5836-5842.
16. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at Accessed January 2, 2013. http://www.eucast.org/clinical_breakpoints/.
17. Howell S.A., Hazen K.C. Candida, Cryptococcus, and other yeasts of medical importance. Manual of clinical microbiology 2011, 1793-1821. ASM Press, Washington, DC. 10th ed. J. Versalovic, K.C. Carroll, G. Funke, J.H. Jorgensen, M.L. Landry, D.W. Warnock (Eds.).
18. Kett D.H., Azoulay E., Echeverria P.M., Vincent J.L. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39:665-670.
19. Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis 2013, 56:1733-1734.
20. Pakyz A.L., Gurgle H.E., Oinonen M.J. Antifungal use in hospitalized adults in U.S. academic health centers. Am J Health Syst Pharm 2011, 68:415-418.
21. Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012, 125:S3-S13.
22. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50:2846-2856.
23. Pfaller M.A., Espinel-Ingroff A., Jones R.N. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol 2004, 42:4577-4580.
24. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Testing TCSfA. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010, 13:180-195.
25. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010, 48:52-56.
26. Pfaller M.A., Castanheira M., Diekema D.J., Messer S.A., Moet G.J., Jones R.N. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010, 48:1592-1599.
27. Pfaller M.A., Andes D., Arendrup M.C., Diekema D.J., Brown S.D., Motyl M., et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011, 70:330-343.
28. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 2011, 49:630-637.
29. Pfaller M.A., Boyken L.B., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. J Clin Microbiol 2011, 49:1274-1279.
30. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14:164-176.
31. Pfaller M.A., Espinel-Ingroff A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) with the 24-h CLSI BMD method for fluconazole, posaconzole, and voriconazole susceptibility testing of Candida species using epidemiological cutoff values. J Clin Microbiol 2011, 49:845-850.
32. Pfaller M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol 2011, 49:396-399.
33. Pfaller M.A., Chaturvedi V., Diekema D.J., Ghannoum M.A., Holliday N.M., Killian S.B., et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn Microbiol Infect Dis 2012, 73:365-368.
34. Pfaller M.A., Espinel-Ingroff A., Castanheira M., Cuenca-Estrella M., Diekema D.J., Fothergill A., et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012, 50:2040-2046.
35. Pfaller M.A., Woosley L.N., Messer S.A., Jones R.N., Castanheira M. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 2012, 174:259-271.
36. Pfaller M.A., Diekema D.J., Procop G.W., Rinaldi M.G. Comparison of the Vitek2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagn Microbiol Infect Dis 2013, 77:37-40.
37. Pfaller M.A., Messer S.A., Rhomberg P.R., Jones R.N., Castanheira M. In vitro activity of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 2013, 51:2608-2616.
38. Pfaller M.A., Messer S.A., Woosley L.N., Jones R.N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011); Application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013, 51:2571-2581.
39. Rodriguez-Tudela J.L., Donnelly J.P., Pfaller M.A., Chryssantou E., Warn P., Denning D.W., et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007, 45:109-111.
40. Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006, 12:418-425.